|

Zipalertinib Matching-placebo Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 3: 1

Top Sponsors

  • Taiho Oncology, Inc.1

Indications

  • Uncommon EGFR Mutations1
  • Early Stage Lung Cancer1
  • Exon 201
  • Post-surgical1
  • NSCLC, Stage IB-IIIA1

Anchorage, Alaska1 trial

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Alaska Oncology and Hematology

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.